EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) is an affiliate and the commercial arm of the European Molecular Biology Laboratory (EMBL). EMBLEM, established in 1999 identifies, protects and commercialises the intellectual property developed in the EMBL-world, from EMBL-alumni and from third parties. EMBLEM facilitates and accelerates the transfer of innovative technology from basic research to industry by working closely with industrial partners spanning the biotech, IT and mechanical/electrical engineering markets to develop new diagnostics, drugs, therapies, machines and devices.
Activities of EMBLEM:
- identification and commercial development of life science technologies;
- patent and copyright protection of Intellectual Property;
- licensing of EMBL technologies to third parties;
- contracting and developing collaborative research agreements;
- marketing and contracting of scientific consultancy services;
- advising and structuring EMBL spin-off companies;
- training and education.
Professional technology transfer and business development company
EMBLEM is a wholly owned subsidiary of EMBL and exclusively responsible for commercialising all intellectual property and associated technologies developed at EMBL, including its outstations in Hinxton (U.K.), Hamburg (Germany), Grenoble (France) and Monterotondo (Italy). EMBLEM is based at the EMBL site in Heidelberg, Germany.
EMBLEM actively identifies, protects, markets and commercialises intellectual property and materials generated by EMBL's research programmes.
The members of our competent team combine a broad range of patenting and business skills and expertise, coupled with research experience. This puts us in a position to talk science with scientists and business with our commercial partners.
The goals of EMBLEM's technology transfer activities are to:
- promote the commercial use of research results and innovations;
- foster exchange between EMBL research and industry;
- return value to stakeholders including society at large;
- support EMBL spin-off companies working in the life sciences;
- increase the attractiveness of EMBL for top researchers by
providing professional technology transfer service;
- create high-tech jobs.
Our staff includes business professionals who assess market opportunities and devise an optimised commercialisation strategy for each individual technology. This may involve the launching of a new enterprise or licensing of the technology to established companies.
We flexibly and pragmatically design agreements with commercial entitites to provide them with a strong incentive to evaluate, develop and exploit the licensed technology- while generating revenues to finance their operations and provide a return on investment to shareholders and licensors.
To systematically market our technology portfolio, we take advantage of a broad international network of business, technology and science contacts and strategic alliances. We endeavour to find as many licensees as required to rapidly deploy an invention in as many applications as possible in the predefined market(s). We ensure that the licensees have the technical expertise and the commercial capabilities to take licensed technology to market including the securing of regulatory approvals.
The EMBL Technology Fund (ETF) has been created to aid the establishment of start-up companies in the Life Sciences from all EMBL Member States. Since our intellectual property portfolio spans a wide range of technologies we can combine them to achieve a better overall package. We have extensive experience in launching new companies, and have good contacts with the organisations needed to make it happen.